Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Provided By GlobeNewswire
Last update: Mar 26, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
Read more at globenewswire.com30.88
+0.74 (+2.46%)
Find more stocks in the Stock Screener
MTSR Latest News and Analysis
